Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mycophenolate mofetil + mycophenolate sodium
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Mycophenolate mofetil + mycophenolate sodium is a combination of two immunosuppressive agents that are both prodrugs of mycophenolic acid. These drugs inhibit inosine monophosphate dehydrogenase (IMPDH), an enzyme crucial for the de novo synthesis of guanosine nucleotides in lymphocytes. By blocking this pathway, they suppress T- and B-lymphocyte proliferation and function, thereby reducing immune-mediated organ rejection after transplantation. Both agents are used to prevent rejection in kidney, heart, or liver transplants and may be used off-label for autoimmune diseases such as lupus nephritis and vasculitis[2][3][4][8]. The two forms differ mainly in their formulation—mycophenolate mofetil is available as immediate-release tablets/capsules/suspension/injection (Cellcept), while mycophenolate sodium is formulated as enteric-coated delayed-release tablets (Myfortic)[7]. They should not be interchanged without physician supervision due to differences in absorption[7].
- Brand names
- CellCeptMyfortic
- Other names
- mycophenolate mofetilmycophenolate sodium
02
Targets
IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on mycophenolate mofetil + mycophenolate sodium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mycophenolate mofetil + mycophenolate sodium.